210 related articles for article (PubMed ID: 35759947)
1. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
3. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
[TBL] [Abstract][Full Text] [Related]
4. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
5. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
6. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
7. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
9. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R
Curr Oncol Rep; 2023 Dec; 25(12):1409-1417. PubMed ID: 37906356
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
[TBL] [Abstract][Full Text] [Related]
11. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
12. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
[TBL] [Abstract][Full Text] [Related]
13. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from drug trials in neurofibromatosis: A systematic review.
Dhaenens BAE; Ferner RE; Evans DG; Heimann G; Potratz C; van de Ketterij E; Kaindl AM; Hissink G; Carton C; Bakker A; Nievo M; Legius E; Oostenbrink R
Eur J Med Genet; 2021 Sep; 64(9):104281. PubMed ID: 34237445
[TBL] [Abstract][Full Text] [Related]
16. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
[TBL] [Abstract][Full Text] [Related]
17. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
[TBL] [Abstract][Full Text] [Related]
18. The Diagnosis and Management of Neurofibromatosis Type 1.
Ly KI; Blakeley JO
Med Clin North Am; 2019 Nov; 103(6):1035-1054. PubMed ID: 31582003
[TBL] [Abstract][Full Text] [Related]
19. Schwannomatosis: a Realm Reborn: year one.
Planet M; Kalamarides M; Peyre M
Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
[TBL] [Abstract][Full Text] [Related]
20. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
